The largest database of trusted experimental protocols

Otx015

Manufactured by Merck Group
Sourced in China, United States

OTX015 is a lab equipment product manufactured by Merck Group. It is designed for general laboratory use. The core function of OTX015 is to perform specific tasks and procedures required in a laboratory setting. No further details about the intended use or specific capabilities of this product can be provided in an unbiased and factual manner.

Automatically generated - may contain errors

4 protocols using otx015

1

CRC Cell Lines and Drug Treatments

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human CRC cell lines, including HCT116, HT29, RKO, SW48, Lim1215, and NCI-H508, were purchased from the American Type Culture Collection and cultured in McCoy’s 5A modified media (Invitrogen). SNU-407 was purchased from AddexBio and cultured in RPMI 1640 (Invitrogen). DR5-knockout (KO) HCT116 cells were previously described (26 (link)). DR5-KO RKO cells were generated by CRISPR/Cas9 using a single guide RNA sequence 5’-CGCGGCGACAACGAGCACAA-3’ as described (27 (link)). Cells were authenticated in 2018 by genotyping and analysis of protein expression by western blotting, and routinely checked for Mycoplasma contamination by PCR. All cell lines were maintained at 37°C and 5% CO2 atmosphere. Cell culture media were supplemented with 10% defined FBS (HyClone), 100 units/ml penicillin, and 100 μg/ml streptomycin (Invitrogen). For drug treatment, cells were plated in 12-well plates at 20–30% density 24 hr before treatment. DMSO (Sigma) stocks of JQ1, I-BET151 (Apexbio), OTX015, I-BET762, 5-FU, and oxaliplatin (Sigma) were prepared and diluted in cell culture media before adding to cells.
+ Open protocol
+ Expand
2

Cell Viability Assay for Drug Screening

Check if the same lab product or an alternative is used in the 5 most similar protocols
MTT assay (Sigma) was used to assess cell viability according to previous descriptions [24]. Briefly, cells were seeded in 96‐well plates at a density of 1000 cells/well and subjected to the following treatments according to experimental requirements: 100 ng/mL Dox (Sigma), 10 µmol/L PD098059 (MedChemExpress, Shanghai, China), or 10 nmol/L OTX015 (Sigma). Cell viability was assessed at 12 h to 60 h. At 60 h post treatment, 200 µL MTT (5 mg/mL) was added in each plate well and incubated for 4 h. After that, the microplate reader (Molecular Devices, San Jose, CA, USA) was used to measure the absorbance value at 490 nm. All experiments were performed in triplicate.
+ Open protocol
+ Expand
3

Microglial Phagocytosis Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Reagents for reverse transcription (High-Capacity cDNA Reverse Transcription Kit with RNase Inhibitor) and quantitative PCR (Taqman Assays, TaqMan OpenArray Mouse Phagocytosis Panel, and TaqMan Fast Advanced Master Mix), red fluorescent microspheres (FMS), 2.0 μm, Hoechst 33342, CellMask Orange Actin Tracking Stain, CellMask Green Actin Tracking Stain, RPMI were obtained from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). Opti-MEM was from Gibco, negative siRNA control was from Ambion, Lipofectamine was from Thermo Fisher Scientific, Inc., Aβ1–42 and Aβ1–42 HiLyte 488 were from AnaSpec, Inc. (Fremont, CA, USA). JQ1, GSK12101517, IBET-762, OTX-015, PFI-1, Cytochalasin D were obtained from Sigma-Aldrich (St. Louis, MO, USA). Heat-inactivated foetal bovine serum (FBS), Accutase solution, penicillin, streptomycin, L-glutamine, 3-(4,5-dimethyl-2-tiazolilo)-2,5-diphenyl-2H-tetrazolium bromide (MTT), propidium iodide, TRI-reagent, DNase I, dithiothreitol (DTT), anhydrous dimethyl sulfoxide (DMSO), lipopolysaccharide from Escherichia coli O55:B5 (toxicity 3,000,000 U/mg), and all other reagents were obtained from Sigma-Aldrich (St. Louis, MO, USA).
+ Open protocol
+ Expand
4

MTT Assay for Cell Viability

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell viability was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay (Sigma-Aldrich). Cells were seeded in 96-well plates at a density of 135.000 cells/mL. Twenty-four hours after seeding, either drug (OTX-015, Sigma-Aldrich) or vehicle (DMSO, Sigma-Aldrich) was added to the media. After 48 h, 10 μL of MTT solution 5 mg/mL (Sigma-Aldrich) was added to each well. Two hours later, MTT was dissolved adding SDS 10% 0.01 M HCl and incubated overnight. The next day, absorbance at 570 nm was measured using a microplate reader (SpectraMax i3x Multi-Mode Microplate Reader, Molecular Devices). Experiments were repeated at least three times and viability was normalised to mean of untreated control, set as 100% viability.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!